Leucemia mielóide aguda na criança: como andamos no Brasil?

Abstract

Pediatric oncology is the sub-specialty which has advanced the most over the last 30 years. A period during which the majority of the specialist centers in Brazil were inaugurated. At all of these centers, leukemias occupy a position of prominence among malign diseases, being predominantly (95-98%) acute. Lymphoid leukemias make up 70 -80% of these. Of the chronic forms of leukemia, only myeloid is manifest among children and adolescents.There are three pathologies that are frustrating to those who work in pediatric oncology in terms of survival: neuroblastoma, acute myeloid leukemia, and central nervous system. The first two because of the unsatisfactory rates achieved even nowadays and the third because of the quality of that survival. We have been working with survival rates above 70% for almost all malignancies, and the fact that we come face to face with rates that oscillate around 30 -40% is, on one hand, discouraging, but on the other hand it stimulates us to fresh research in an attempt to discover what goes on in the interior of a malignant cell that makes it more or less aggressive and more or less responsive to chemotherapy and radiotherapy.

Osteoarticular Manifestations as Initial Presentation of Acute Leukemias in Children and Adolescents in Bahia, Brazil

“…The most common referring misdiagnosis in the literature is JIA, especially the systemic onset subtype. [15][16][17][18] RF was the most frequent rheumatologic diagnostic described in this series of patients, in disagreement with other authors who refer to JIA as the most important rheumatologic differential diagnostic. [19][20][21][22] The incidence of RF in the developing countries may be 100 to 206/ 100,000 children, with a prevalence of 2.1/1000 poor families.…”

Avaliação de eventos infecciosos oportunistas em crianças portadoras de leucemias

“…6 As mais comuns são as agudas, predominantemente as linfóides (LLA), que correspondem por 70% a 80% dos casos e, em menor número, as mielóides (LMA), compreendendo apenas 15%. 1,7 A única leucemia crônica que se manifesta em crianças e adolescentes é a de origem mielóide (LMC), 7 representando menos de 1% das leucemias pediátricas. 8 Uma das principais complicações do paciente leucêmico é a imunossupressão decorrente da própria doença e/ ou induzida pela quimioterapia.…”

Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents with Acute Myeloid Leukemia in Brazil: A Multicentric Retrospective Study

“…Many patients do not undergo a proper cytogenetic and molecular evaluation and classification of their disease at diagnosis, and they may not be treated using standardized treatment protocols. In these countries, there is a limited number of hospital beds available for chemotherapy or transplantation, and optimal supportive care and management of comorbidities may not be available, compromising cure rates and increasing the risks associated with these complex and expensive procedures [13][14][15][16][17][18] .…”